8
1
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
TP1976 |
Oxyntomodulin
胃泌酸调节素,Oxyntomodulin (porcine, bovine) |
||
GLP-1 receptor agonist. Endogenous preproglucagon-derived neuropeptide that modulates feeding and metabolism. Also secreted by intestinal L-cells. Increases cAMP production and inhibits gastric acid secretion in rat stomach. Also weak glucagon receptor ag | |||
TP1976L |
Oxyntomodulin acetate
|
Glucagon Receptor | GPCR/G Protein |
Oxyntomodulin acetate 是一种 37 个氨基酸的肽激素,是一种胰高血糖素样肽 1 (GLP-1) 受体激动剂。 | |||
T76328 |
Oxyntomodulin (swine)
|
||
Oxyntomodulin (swine) 是一种肽类激素,在餐后状态下从肠道释放,作为GLP-1R(GLP-1 受体) 和GCGR(胰高血糖素受体) 的双重激动剂,能够抑制食欲并减少食物摄入。 | |||
T75824 |
Oxyntomodulin TFA
|
||
Oxyntomodulin TFA 是一种含 37 个氨基酸的肽激素,是胰高血糖素样肽 1 (GLP-1) 受体激动剂。 | |||
T81585 |
Oxyntomodulin (human, mouse, rat)
Proglucagon (33-69) |
||
Oxyntomodulin (human, mouse, rat) (Proglucagon (33-69)) 是由胰高血糖素前体产生,融合了完整胰高血糖素序列和C端八肽,含37个氨基酸。 | |||
T80030 |
Oxyntomodulin (bovine, porcine) (TFA)
Glucagon-37 (bovine, porcine) (TFA) |
||
Oxyntomodulin (bovine, porcine) TFA为含37个氨基酸的肽类激素,作为胰高血糖素样肽1 (GLP-1) 受体的激动剂。 | |||
T80079 |
Mazdutide TFA
LY-3305677 TFA,IBI-362 TFA,OXM-3 TFA |
||
Mazdutide (IBI-362; LY-3305677) TFA 是一款GLP-1R与GCGR的共激动剂,同时是长效合成胃泌酸调节素类似物。该化合物安全性和耐受性良好,适用于肥胖与T2D研究。 | |||
T78097 |
Mazdutide
IBI-362,LY-3305677,OXM-3 |
||
Mazdutide (IBI-362; LY-3305677) 是一种具有安全性和耐受性的胃泌酸调节素类似物,用于肥胖和2型糖尿病(T2D)的研究。它同时作为胰高血糖素样肽(GLP-1R)和胰高血糖素受体(GCGR)的共激动剂,表现出长效作用。 |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPJ-00742 |
GCG Protein, Human, Recombinant (His)
Glicentin,GRPP,GLP-2,Glucagon-Like Peptide 1,OXM,Glucagon,GL... |
Human | HEK293 Cells |
Glucagon is a secreted protein and belongs to the glucagon family. Glucagon can be cleved into 8 chains, playing an important role in initiating and maintaining hyperglycemic conditions in diabetes. Glucagon can regulates blood glucose by decreasing glycolysis and increasing gluconeogenesis. In addition, Glucagon is involved in initiating and maintaining hyperglycemic conditions in diabetes. Glucagon release is stimulated by hypoglycemia and inhibited by hyperglycemia, insulin, and somatostatin.... |